Trial
NCT03451825
Phase I/II Study of Avelumab in Pediatric Cancer Participants
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Refractory or Relapsed Solid Tumors
Intervention
Avelumab
Why stopped
Based on the limited activity observed with avelumab monotherapy in the pediatric population, the Phase II study part was cancelled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-24